Interleukin (IL)

Interleukins (ILs) constitute a broad class of cytokines produced by immune and non-immune cells that regulate immune responses, inflammation, cell growth, and differentiation. These signalling proteins act through specific receptors, activating intracellular pathways that coordinate immune cell communication and response magnitude. Different interleukins perform distinct roles, with some promoting inflammation while others suppress immune responses and maintain tolerance.

The biopharmaceutical industry targets interleukin pathways across multiple therapeutic areas including autoimmune diseases, inflammatory disorders, cancer, and infectious diseases. Therapeutic strategies include monoclonal antibodies blocking interleukins such as IL-6, IL-17, or IL-23 to reduce pathological inflammation, or recombinant interleukins stimulating immune activation in oncology. Interleukin levels serve as biomarkers reflecting disease activity, treatment response, or immune-related toxicity. Safety monitoring is essential as interleukin modulation can increase infection risk or trigger immune imbalance. As immune biology advances and precision immunomodulation becomes increasingly feasible, interleukin research continues driving development of targeted therapies improving outcomes across immune-mediated diseases.